---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-229231"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:48:43.299938+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics transfers to Nasdaq Capital Market; extended bid price deadline to March 2026

## Summary
- Company received approval on Oct 2, 2025 to transfer listing from Nasdaq Global Select to Capital Market, effective Oct 6.
- Transfer follows failure to meet $1.00 minimum bid price requirement for continued Global Select listing.
- Nasdaq granted additional 180-day period until March 30, 2026 to regain compliance with minimum bid price.
- Stock must close at $1.00+ for 10 consecutive business days to regain compliance; company evaluating options.
- Common stock continues to trade under symbol XLO on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001193125-25-229231
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/0001193125-25-229231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/d74952d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-229231
- JSON: https://secwatch.observer/filing/0001193125-25-229231.json
- Plain text: https://secwatch.observer/filing/0001193125-25-229231.txt

## Source-grounded claims
- claim_id: a5d02972f4cf54cb438c12d1056de412443bddff
  claim: Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(H)).
  evidence_excerpt: April 8, 2025 , the Company received a letter from the Staff of Nasdaq notifying the Company of its failure to maintain the $1.00 minimum bid price required for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In connection with the transfer to The Nasdaq Capital Market, Nasdaq granted the Company an additional 180 calendar day period, or until March 30, 2026, to regain compliance with the Minimum Bid Price Requirement. During the additional 180 calendar day grace period, the Company’s common stock must close at $1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/0001193125-25-229231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.